cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.57745/k6unpu
title: 11-UtilisationOutil.tab

description: Ce fichier présente l'utilisation ou non de l'outil de génération de data paper, uniquement pour ceux qui connaissaient déjà l'outil.
DOI: 10.57745/hakjfy
title: 03-DomaineRecherche.tab

description: Statistiques sur le domaine d'appartenance des répondants. Les répondants avaient la possibilité de remplir plusieurs domaines de recherche à la fois.
DOI: 10.57745/jpwmtb
title: 10-DomaineAutreVsDP.tab

description: Ce fichier présente les résultats du croisement entre la colonne "Domaine Autre" et la colonne portant sur la "publication de data papers".
DOI: 10.57745/wlc0mi
title: 06-DomainesVSRevues.tab

description: Statistiques sur le croisement entre le domaine d'appartenance des répondants et la revue utilisée.
DOI: 10.57745/6qabsu
title: Readme_fr.md

description: Ce fichier décrit le contexte de production des données
DOI: 10.57745/kqfodr
title: 12-UtilisationOutilVSRevuesPubliees.tab

description: Ce fichier présente les répondants ayant publiés uniquement dans une revue et ayant utilisés l'outil de génération de data paper proposé par l'entrepôt Recherche Data Gouv.
DOI: 10.57745/kmdsqt
title: 02-Etablissements.tab

description: Ce fichier présente les établissements d'appartenance des répondants.
DOI: 10.57745/pscfcn
title: 05-StatutvsPublicationDataPaper.tab

description: Ce fichier présente le croisement de la colonne portant sur le statut et celle axée sur la publication de data paper.
DOI: 10.57745/02etle
title: ResultatEnquete.tab

description: Fichier de base pour analyse.
DOI: 10.6084/m9.figshare.22692063
title: <i>In silico</i> and <i>in vivo</i> demonstration of the regulatory mechanism of Qi-Ge decoction in treating NAFLD

description: Nonalcoholic fatty liver disease (NAFLD), a chronic and progressive liver disease, often causes steatosis and steatohepatitis. Qi-Ge decoction (QGD) shows a good effect against NAFLD in the clinic. But the molecular mechanism for QGD in improving NAFLD is unknown. This study explored the molecular mechanism of QGD in NAFLD model rats using comprehensive network pharmacology, molecular docking and <i>in vivo</i> verification strategies. Active components and targets of QGD were obtained from public database. The overlapped genes between QGD and NAFLD targets were analyzed by enrichment analysis. Active components and targets were used to predict molecular docking analysis. Finally, seven key targets were screened out and the gene expression were verified in the NAFLD rat’s liver tissues after QGD treatment. Fifty-eight common QGD therapeutic targets were associated with NAFLD. Molecular docking demonstrated that seven targets had strong binding ability for the corresponding active ingredients. GO analysis identified 18 biological process entries, which were mainly related to regulation of lipid storage, lipid localization and peptide transport. KEGG analysis identified multiple signaling pathways, which were mainly associated with tumor necrosis factor signaling and NAFLD. <i>In vivo</i> data confirmed that the effect of QGD in the treatment of NAFLD was mainly exerted through improving liver steatosis and inflammatory cell infiltration. Additionally, QGD upregulated the expression of MAPK8 and ESR1 and downregulated the transcriptional expression of IL6, VEGFA, CASP3, EGFR and MYC. These targets may affect lipid metabolism by regulating lipid storage and inflammation. The integration of results obtained <i>in silico</i> and <i>in vivo</i> indicated that QGD regulates multiple targets, biological processes and signaling pathways in NAFLD, which may represent a complex molecular mechanism by which QGD improves NAFLD.Key messagesQGD intervention is related to multiple biological processes such as inflammation, oxidation and cell apoptosis in NAFLD.Lipid and atherosclerosis, TNF signaling pathway, IL-17 signaling pathway, non-alcoholic fatty liver disease and AGE-RAGE signaling pathway in diabetic complications are the main pathways for QGD intervention NAFLD.The active components of QGD can form good binding with relevant target proteins through intermolecular forces, exhibiting excellent docking activity. QGD intervention is related to multiple biological processes such as inflammation, oxidation and cell apoptosis in NAFLD. Lipid and atherosclerosis, TNF signaling pathway, IL-17 signaling pathway, non-alcoholic fatty liver disease and AGE-RAGE signaling pathway in diabetic complications are the main pathways for QGD intervention NAFLD. The active components of QGD can form good binding with relevant target proteins through intermolecular forces, exhibiting excellent docking activity.
DOI: 10.6084/m9.figshare.22692063.v1
title: <i>In silico</i> and <i>in vivo</i> demonstration of the regulatory mechanism of Qi-Ge decoction in treating NAFLD

description: Nonalcoholic fatty liver disease (NAFLD), a chronic and progressive liver disease, often causes steatosis and steatohepatitis. Qi-Ge decoction (QGD) shows a good effect against NAFLD in the clinic. But the molecular mechanism for QGD in improving NAFLD is unknown. This study explored the molecular mechanism of QGD in NAFLD model rats using comprehensive network pharmacology, molecular docking and <i>in vivo</i> verification strategies. Active components and targets of QGD were obtained from public database. The overlapped genes between QGD and NAFLD targets were analyzed by enrichment analysis. Active components and targets were used to predict molecular docking analysis. Finally, seven key targets were screened out and the gene expression were verified in the NAFLD rat’s liver tissues after QGD treatment. Fifty-eight common QGD therapeutic targets were associated with NAFLD. Molecular docking demonstrated that seven targets had strong binding ability for the corresponding active ingredients. GO analysis identified 18 biological process entries, which were mainly related to regulation of lipid storage, lipid localization and peptide transport. KEGG analysis identified multiple signaling pathways, which were mainly associated with tumor necrosis factor signaling and NAFLD. <i>In vivo</i> data confirmed that the effect of QGD in the treatment of NAFLD was mainly exerted through improving liver steatosis and inflammatory cell infiltration. Additionally, QGD upregulated the expression of MAPK8 and ESR1 and downregulated the transcriptional expression of IL6, VEGFA, CASP3, EGFR and MYC. These targets may affect lipid metabolism by regulating lipid storage and inflammation. The integration of results obtained <i>in silico</i> and <i>in vivo</i> indicated that QGD regulates multiple targets, biological processes and signaling pathways in NAFLD, which may represent a complex molecular mechanism by which QGD improves NAFLD.Key messagesQGD intervention is related to multiple biological processes such as inflammation, oxidation and cell apoptosis in NAFLD.Lipid and atherosclerosis, TNF signaling pathway, IL-17 signaling pathway, non-alcoholic fatty liver disease and AGE-RAGE signaling pathway in diabetic complications are the main pathways for QGD intervention NAFLD.The active components of QGD can form good binding with relevant target proteins through intermolecular forces, exhibiting excellent docking activity. QGD intervention is related to multiple biological processes such as inflammation, oxidation and cell apoptosis in NAFLD. Lipid and atherosclerosis, TNF signaling pathway, IL-17 signaling pathway, non-alcoholic fatty liver disease and AGE-RAGE signaling pathway in diabetic complications are the main pathways for QGD intervention NAFLD. The active components of QGD can form good binding with relevant target proteins through intermolecular forces, exhibiting excellent docking activity.
DOI: 10.6084/m9.figshare.23592808
title: Risk of vascular diseases in patients with dermatitis herpetiformis and coeliac disease: a long-term cohort study

description: Dermatitis herpetiformis (DH) is a cutaneous manifestation of coeliac disease. Increased cardiovascular morbidity has been reported in coeliac disease, but in DH only little is known about this. In this cohort study with a long-term follow-up, the risk for vascular diseases in patients with dermatitis herpetiformis (DH) and coeliac disease was assessed. The study consisted of 368 DH and 1072 coeliac disease patients with biopsy-proven diagnosis performed between 1966 and 2000. For each DH and coeliac disease patient three matched reference individuals were obtained from the population register. Data regarding all outpatient and inpatient treatment periods between 1970 and 2015 were reviewed for diagnostic codes of vascular diseases from the Care Register for Health Care. Cox proportional hazard model was used to assess the risks for the diseases studied and the HRs were adjusted for diabetes mellitus (aHR). The median follow-up time of DH and coeliac disease patients was 46 years. The risk for cardiovascular diseases did not differ between DH patients and their references (aHR 1.16, 95% CI 0.91–1.47), but among coeliac disease patients, the risk was increased (aHR 1.36, 95% CI 1.16–1.59). The risk for cerebrovascular diseases was found to be decreased in DH patients when compared with references (aHR 0.68, 95% CI 0.47–0.99) and increased in coeliac disease patients (aHR 1.33, 95% CI 1.07–1.66). The risk for venous thrombosis was increased in coeliac disease patients (aHR 1.62, 95% CI 1.22–2.16) but not in DH. The risk for vascular complications appears to differ between DH and coeliac disease. In DH the risk for cerebrovascular diseases seems to be decreased, while in coeliac disease an elevated risk for cerebrovascular and cardiovascular diseases was observed. These differing vascular risk profiles between the two manifestations of the same disease merit further investigation. An increased risk for cardiovascular diseases was observed among patients with coeliac disease, but not among patients with dermatitis herpetiformis, a cutaneous manifestation of coeliac disease.The risk for cerebrovascular diseases was shown to be decreased in dermatitis herpetiformis patients, but conversely, an increased risk for cerebrovascular diseases was identified in coeliac disease patients.Coeliac disease, but not dermatitis herpetiformis, was shown to be associated with increased risk for venous thrombosis. An increased risk for cardiovascular diseases was observed among patients with coeliac disease, but not among patients with dermatitis herpetiformis, a cutaneous manifestation of coeliac disease. The risk for cerebrovascular diseases was shown to be decreased in dermatitis herpetiformis patients, but conversely, an increased risk for cerebrovascular diseases was identified in coeliac disease patients. Coeliac disease, but not dermatitis herpetiformis, was shown to be associated with increased risk for venous thrombosis.
DOI: 10.6084/m9.figshare.23592808.v1
title: Risk of vascular diseases in patients with dermatitis herpetiformis and coeliac disease: a long-term cohort study

description: Dermatitis herpetiformis (DH) is a cutaneous manifestation of coeliac disease. Increased cardiovascular morbidity has been reported in coeliac disease, but in DH only little is known about this. In this cohort study with a long-term follow-up, the risk for vascular diseases in patients with dermatitis herpetiformis (DH) and coeliac disease was assessed. The study consisted of 368 DH and 1072 coeliac disease patients with biopsy-proven diagnosis performed between 1966 and 2000. For each DH and coeliac disease patient three matched reference individuals were obtained from the population register. Data regarding all outpatient and inpatient treatment periods between 1970 and 2015 were reviewed for diagnostic codes of vascular diseases from the Care Register for Health Care. Cox proportional hazard model was used to assess the risks for the diseases studied and the HRs were adjusted for diabetes mellitus (aHR). The median follow-up time of DH and coeliac disease patients was 46 years. The risk for cardiovascular diseases did not differ between DH patients and their references (aHR 1.16, 95% CI 0.91–1.47), but among coeliac disease patients, the risk was increased (aHR 1.36, 95% CI 1.16–1.59). The risk for cerebrovascular diseases was found to be decreased in DH patients when compared with references (aHR 0.68, 95% CI 0.47–0.99) and increased in coeliac disease patients (aHR 1.33, 95% CI 1.07–1.66). The risk for venous thrombosis was increased in coeliac disease patients (aHR 1.62, 95% CI 1.22–2.16) but not in DH. The risk for vascular complications appears to differ between DH and coeliac disease. In DH the risk for cerebrovascular diseases seems to be decreased, while in coeliac disease an elevated risk for cerebrovascular and cardiovascular diseases was observed. These differing vascular risk profiles between the two manifestations of the same disease merit further investigation. An increased risk for cardiovascular diseases was observed among patients with coeliac disease, but not among patients with dermatitis herpetiformis, a cutaneous manifestation of coeliac disease.The risk for cerebrovascular diseases was shown to be decreased in dermatitis herpetiformis patients, but conversely, an increased risk for cerebrovascular diseases was identified in coeliac disease patients.Coeliac disease, but not dermatitis herpetiformis, was shown to be associated with increased risk for venous thrombosis. An increased risk for cardiovascular diseases was observed among patients with coeliac disease, but not among patients with dermatitis herpetiformis, a cutaneous manifestation of coeliac disease. The risk for cerebrovascular diseases was shown to be decreased in dermatitis herpetiformis patients, but conversely, an increased risk for cerebrovascular diseases was identified in coeliac disease patients. Coeliac disease, but not dermatitis herpetiformis, was shown to be associated with increased risk for venous thrombosis.
DOI: 10.6084/m9.figshare.23219719
title: Improving clinical outcomes of Barrett’s esophagus with high dose proton pump inhibitors and cryoablation

description: Esophageal adenocarcinoma incidence has increased significantly despite surveillance endoscopy for Barrett’s esophagus (BE) and gastric acid supression medications. This prospective, cohort study’s aims were to determine the long-term efficacy of proton-pump inhibitors twice daily (PPI-BID) with cryotherapy (CRYO) for complete ablation of BE. Consecutive BE patients were managed with a PPI-BID, CRYO ablation, follow-up protocol. Primary outcomes were to determine complete ablation rate of intestinal metaplasia (IM) or dysplasia/carcinoma, and factors affecting recurrence. Sixty-two patients were enrolled: advanced disease (11%), low-grade or indefinite dysplasia (26%), non-dysplastic BE (63%). In 58 completing CRYO, eradication was confirmed in 100% on surveillance endoscopy. Adverse events (5%) were minor (mild pain 4%). IM recurred in 9% after a mean of 52 months, all successfully re-ablated. No second recurrence occurred. The primary predictor of recurrence was noncompliance with PPI-BID. BE or cardia IM recurred in 35% of those taking proton pump inhibitors once daily or less compared with 0% in those on PPI-BID or dexlansoprazole daily (<i>p</i>&lt;.001). Minimizing acid reflux with at least PPI-BID combined with CRYO ablation appears to be the optimal cost-effective and safe BE treatment for any stage to minimize progression to adenocarcinoma by addressing both the stimulus that causes BE and the presence of goblet cells. Endoscopic surveillance of Barrett’s esophagus (BE) has not made any clear impact on incidence of or mortality from esophageal adenocarcinoma.After cost-effective, safe cryoablation of BE, continued effective acid-reflux control with high-dose proton pump inhibitors is critical to minimize recurrence or progression.Risk factors and costs will define methods and frequency of limited surveillance after ablation of BE. Endoscopic surveillance of Barrett’s esophagus (BE) has not made any clear impact on incidence of or mortality from esophageal adenocarcinoma. After cost-effective, safe cryoablation of BE, continued effective acid-reflux control with high-dose proton pump inhibitors is critical to minimize recurrence or progression. Risk factors and costs will define methods and frequency of limited surveillance after ablation of BE.
DOI: 10.6084/m9.figshare.23219719.v1
title: Improving clinical outcomes of Barrett’s esophagus with high dose proton pump inhibitors and cryoablation

description: Esophageal adenocarcinoma incidence has increased significantly despite surveillance endoscopy for Barrett’s esophagus (BE) and gastric acid supression medications. This prospective, cohort study’s aims were to determine the long-term efficacy of proton-pump inhibitors twice daily (PPI-BID) with cryotherapy (CRYO) for complete ablation of BE. Consecutive BE patients were managed with a PPI-BID, CRYO ablation, follow-up protocol. Primary outcomes were to determine complete ablation rate of intestinal metaplasia (IM) or dysplasia/carcinoma, and factors affecting recurrence. Sixty-two patients were enrolled: advanced disease (11%), low-grade or indefinite dysplasia (26%), non-dysplastic BE (63%). In 58 completing CRYO, eradication was confirmed in 100% on surveillance endoscopy. Adverse events (5%) were minor (mild pain 4%). IM recurred in 9% after a mean of 52 months, all successfully re-ablated. No second recurrence occurred. The primary predictor of recurrence was noncompliance with PPI-BID. BE or cardia IM recurred in 35% of those taking proton pump inhibitors once daily or less compared with 0% in those on PPI-BID or dexlansoprazole daily (<i>p</i>&lt;.001). Minimizing acid reflux with at least PPI-BID combined with CRYO ablation appears to be the optimal cost-effective and safe BE treatment for any stage to minimize progression to adenocarcinoma by addressing both the stimulus that causes BE and the presence of goblet cells. Endoscopic surveillance of Barrett’s esophagus (BE) has not made any clear impact on incidence of or mortality from esophageal adenocarcinoma.After cost-effective, safe cryoablation of BE, continued effective acid-reflux control with high-dose proton pump inhibitors is critical to minimize recurrence or progression.Risk factors and costs will define methods and frequency of limited surveillance after ablation of BE. Endoscopic surveillance of Barrett’s esophagus (BE) has not made any clear impact on incidence of or mortality from esophageal adenocarcinoma. After cost-effective, safe cryoablation of BE, continued effective acid-reflux control with high-dose proton pump inhibitors is critical to minimize recurrence or progression. Risk factors and costs will define methods and frequency of limited surveillance after ablation of BE.
DOI: 10.15468/dl.fxcz89
title: Occurrence Download

description: A dataset containing 9137 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Ipomoea cairica (L.) Sweet"
 ]
}

 The dataset includes 9137 records from 272 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0101683-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.rw0php
title: Occurrence Download

description: A dataset containing 3717 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Year 1000-2018",
 "TaxonKey is Vigna luteola (Jacq.) Benth."
 ]
}

 The dataset includes 3717 records from 163 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009361-180131172636756/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.n72dad
title: Occurrence Download

description: A dataset containing 8403 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 }
 ]
 },
 "TaxonKey is Emberiza fucata Pallas, 1776"
 ]
}

 The dataset includes 8403 records from 44 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0027584-240314170635999/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.rt52ay
title: Occurrence Download

description: A dataset containing 902 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Tuta absoluta (Meyrick, 1917)"
 ]
}

 The dataset includes 902 records from 19 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0101685-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.g2rfs7
title: Occurrence Download

description: A dataset containing 43745 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Trifolium aureum Pollich"
 ]
}

 The dataset includes 43745 records from 817 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0132715-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.m39wy9
title: Occurrence Download

description: A dataset containing 111 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Diaphanodon blandus (Harv.) Renauld & Cardot"
 ]
}

 The dataset includes 111 records from 20 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0088281-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.cjt7rc
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is one of (Dangeardinellaceae)"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0027650-240314170635999/datasets/export for details.
DOI: 10.15468/dl.j4maps
title: Occurrence Download

description: A dataset containing 777305 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-191.77734 66.62109,-220.95703 60.64453,-228.69141 53.96484,-222.01172 50.44922,-230.09766 44.12109,-242.05078 42.36328,-244.51172 36.73828,-241.34766 27.59766,-237.48047 10.01953,-234.31641 -3.33984,-222.01172 -11.07422,-213.57422 -24.08203,-213.22266 -34.27734,-215.68359 -47.98828,-206.54297 -86.30859,-71.89453 -85.95703,-62.40234 -65.21484,-72.24609 -49.39453,-66.62109 -14.23828,-76.11328 -9.66797,-74.35547 3.69141,-92.28516 16.69922,-103.18359 19.86328,-119.70703 37.79297,-124.62891 49.04297,-131.66016 57.83203,-147.83203 62.40234,-166.46484 66.62109,-191.77734 66.62109))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 {
 "or" : [
 "TaxonKey is Pelecanus occidentalis Linnaeus, 1766",
 "TaxonKey is Pelecanus erythrorhynchos Gmelin, 1789"
 ]
 }
 ]
}

 The dataset includes 777305 records from 100 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0344319-200613084148143/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.qslho6
title: Occurrence Download

description: A dataset containing 285 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Vigna radicans Welw. ex Baker"
 ]
}

 The dataset includes 285 records from 15 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0009360-180131172636756/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.